Windlas Biotech Limited

NSE WINDLAS.NS

Windlas Biotech Limited Return on Capital Employed (ROCE) for the year ending March 31, 2024: 17.21%

Windlas Biotech Limited Return on Capital Employed (ROCE) is 17.21% for the year ending March 31, 2024, a 21.32% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Windlas Biotech Limited Return on Capital Employed (ROCE) for the year ending March 31, 2023 was 14.18%, a 19.85% change year over year.
Windlas Biotech Limited Return on Capital Employed (ROCE) for the year ending March 31, 2022 was 11.83%, a 3.38% change year over year.
Windlas Biotech Limited Return on Capital Employed (ROCE) for the year ending March 31, 2021 was 11.45%, a -29.59% change year over year.
Windlas Biotech Limited Return on Capital Employed (ROCE) for the year ending March 31, 2020 was 16.26%, a -59.82% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NSE: WINDLAS.NS

Windlas Biotech Limited

CEO	Ms. Komal Gupta
IPO Date	Aug. 16, 2021
Location	India
Headquarters	705-706, Vatika Professional Point
Employees	1,154
Sector	Healthcare
Industries Specialty Retail Consumer Packaged Goods Drugstores & Retail Pharmacies Fertilizers Pharmaceuticals

Description

Windlas Biotech Limited operates as a contract development and manufacturing organization (CDMO). Its CDMO services include product discovery, product development, licensing, and commercial manufacturing generic products, including generic products. The company provides its CMDO products and services across a range of pharmaceutical and nutraceutical conventional, and novel products for customers who market such products under their own brand names to the end users. It also offers manufactures various domestic trade generics and over-the-counter brand product portfolio to cater to nutritional, ayurvedic, wellness, and personal care markets. The company's domestic trade generics and OTC brands products are distributed through the offline channel, such as distributors, stockists, retail pharmacies, and institutional tenders, as well as the online channel, such as various e-commerce platforms. It exports its products primarily to Vietnam, Myanmar, Sri Lanka, Thailand, the Philippines, Cambodia, Fiji, Trinidad & Tobago, and South Africa. The company was incorporated in 2001 and is based in Gurugram, India.

Key trends

Past 5 years